CareDx Inc (CDNA) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

CareDx Inc (CDNA)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

21.98

-3.09 (-12.33%)

At close: Jan 14, 2025, 3:59 PM

22.31

1.52%

Pre-market Jan 15, 2025, 05:00 AM EST

undefined% (undefined)

Bid	22.43
Market Cap	1.18B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-2.69
PE Ratio (ttm)	-8.17
Forward PE	n/a
Analyst	Hold

Ask	33
Volume	1,193,542
Avg. Volume (20D)	815,218
Open	25.30
Previous Close	25.07
Day's Range	21.83 - 25.93
52-Week Range	7.42 - 34.84
Beta	undefined

About CDNA

CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The co...

[Show more]

Industry Medical - Diagnostics & Research

Sector Healthcare

IPO Date Jul 17, 2014

Employees 635

Stock Exchange NASDAQ

Ticker Symbol CDNA

Website https://www.caredx.com

Analyst Forecast

According to 7 analyst ratings, the average rating for CDNA stock is "Hold." The 12-month stock price forecast is $30, which is an increase of 36.52% from the latest price.

Buy 57.14%

Hold 28.57%

Sell 14.29%

Stock Forecasts

Next Earnings Release

CareDx Inc is scheduled to release its earnings on Feb 26, 2025, during market hours.
Analysts project revenue of $82.16M, reflecting a 25.30% YoY growth and earnings per share of 0.05, making a -129.41% decrease YoY.

Why Price Moved

3 months ago · Source

-15.84%

CareDx shares are trading lower. The company repor... Unlock content with Pro Subscription

5 months ago · Source

+16.4%

CareDx shares are trading higher after the CMS retired a draft policy that would have restricted coverage for non-invasive blood-based surveillance testing for allograft rejection.

News

1 day ago · zacks.com

Strength Seen in CareDx (CDNA): Can Its 6.1% Jump Turn into More Strength?

CareDx (CDNA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in t...

2 days ago · businesswire.com

CareDx Announces Preliminary Fourth Quarter and Full Year 2024 Results

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – today reported preliminary, unaudited financial results for the fourth quarter and full year ended December 3...

3 weeks ago · seekingalpha.com

CareDx: Top Of My Shopping List For 2025

CareDx is a promising candidate for the Bioreactor growth portfolio due to its leadership in transplant diagnostics and significant growth potential despite previous concerns. The company has shown st...

4 weeks ago · businesswire.com

CareDx to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) - The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinical...

1 month ago · zacks.com

Has CareDx (CDNA) Outpaced Other Medical Stocks This Year?

Here is how CareDx (CDNA) and Clover Health Investments, Corp. (CLOV) have performed compared to their sector so far this year.

1 month ago · zacks.com

Wall Street Analysts Predict a 49.89% Upside in CareDx (CDNA): Here's What You Should Know

The consensus price target hints at a 49.9% upside potential for CareDx (CDNA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate r...

2 months ago · zacks.com

After Plunging -11.97% in 4 Weeks, Here's Why the Trend Might Reverse for CareDx (CDNA)

The heavy selling pressure might have exhausted for CareDx (CDNA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in ...

2 months ago · zacks.com

Are Medical Stocks Lagging CareDx (CDNA) This Year?

Here is how CareDx (CDNA) and Doximity (DOCS) have performed compared to their sector so far this year.

2 months ago · businesswire.com

CareDx to Participate in Upcoming Investor Conferences

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinical...

2 months ago · seekingalpha.com

CareDx, Inc (CDNA) Q3 2024 Earnings Call Transcript

CareDx, Inc (NASDAQ:CDNA ) Q3 2024 Earnings Conference Call November 4, 2024 4:30 PM ET Company Participants Greg Chodaczek - Managing Director John Hanna - President and Chief Executive Officer Abhis...

3 months ago · benzinga.com

CareDx, JD.com And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

U.S. stock futures were slightly higher this morning, with the Dow futures gaining around 10 points on Tuesday.

3 months ago · businesswire.com

CareDx Reports Preliminary Financial Results for Third Quarter 2024